Aspen Pharmacare Hldgs (APNHF) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen in the room, and those of you joining us via webcast today. It is my pleasure to welcome you to the financial results of the first six months of Aspen's results, financial year, sorry. My name is Bongagon Gengosi, and I'm the Group Investor Relations Manager here at Aspen. In today's proceedings, you'll be hearing from Stephen Saad, the Group Chief Executive, who will be providing you with insightful overview of our results, taking us through the revenue performance of the group and its segments. Notably, we have revised the segmental reporting both in commercial pharma and manufacturing. These new segments give improved insights, understanding, and more granular disclosure. We've also bolstered the appendices to provide more detailed analysis In the appendices, you will find a comparison of the revenue disclosure between the old and the new reporting segments for commercial pharma and manufacturing. Also included in the appendices is a table illustrating the currency contribution of the group at a revenue and an EBITDA level. This will facilitate a deeper understanding of the dynamics between constant currency and reported performance. In the financial highlights, or as you dive deeper into the financial highlights and the finance cost slides, we've also updated the capital allocation framework, emphasizing that share buybacks fall within the fourth quadrant of our investment options alongside strategic M&A. And in the projected CapEx slide, you will see an uptick in the FY24 numbers. We expect a slight uptick in the numbers in order to meet evolving customer needs and market demands. However, we do anticipate that this will taper down in FY25, and you should see a resulting impact of lower FY25 spend from FY25 onwards. And with th...